

S6 Table. Time to onset and resolution of all-grade immune-related adverse events based on cancer types under the treatment of NIV 3 mg/kg Q2W

	Lung cancer	Melanoma
All categories		
No. of patients with irAE	292 (7.9)	1,036 (14.3)
Time to onset (wk)	5.7 (4.5-11.2)	8.4 (7.7-10.4)
No. of patients with irAE	141 (85.5)	722 (70.0)
Time to resolution (wk)	5.9 (2.3-10.1) ^{a)}	22.1 (2.4-28.6) ^{a)}
Skin		
No. of patients with irAE	104 (19.7)	451 (43.7)
Time to onset (wk)	5.7 (2.9-5.7)	6.1 (5.7-8.4)
No. of patients with resolution	58 (87.9)	277 (61.8)
Time to resolution (wk)	10.1 (10.1-10.1) ^{a)}	28.6 (22.1-35.1) ^{a)}
Gastrointestinal		
No. of patients with irAE	47 (8.9)	237 (22.9)
Time to onset (wk)	4.5 (4.5-22.4)	10.9 (7.7-11.1)
No. of patients with resolution	34 (94.4)	212 (90.2)
Time to resolution (wk)	2.3 (2.3-2.3)	2.4 (1.9-2.4)
Hepatic		
No. of patients with irAE	30 (5.7)	95 (9.2)
Time to onset (wk)	8.0 (2.0-8.0) ^{a)}	14.1 (12.3-16.0) ^{a)}
No. of patients with resolution	17 (73.9)	84 (88.4)
Median time to resolution, weeks (95% CI)	4.0 (4.0-4.0)	6.1 (3.3-7.9)
Endocrine		
No. of patients with irAE	53 (10.0)	181 (17.5)
Time to onset (wk)	11.2 (11.2-11.2) ^{a)}	8.2 (8.2-12.1) ^{a)}
No. of patients with resolution	-	94 (51.9)
Time to resolution (wk)	NA	48.1 (28.7-48.1)
Pulmonary		
No. of patients with irAE	25 (4.7)	20 (1.9)
Time to onset (wk)	27.9 (4.8-27.9) ^{a)}	8.7 (7.8-8.9) ^{a)}
No. of patients with resolution	16 (84.2)	14 (70.0)
Time to resolution (wk)	5.9 (5.9-5.9)	5.8 (4.7-15.1)

Renal

No. of patients with irAE	17 (3.2)	17 (1.6)
Time to onset (wk)	8.2 (8.2-17.8)	15.4 (14.2-102.0)
No. of patients with resolution	6 (54.5)	11 (64.7)
Time to resolution (wk)	10.5 (10.5-10.5)	10.5 (5.4-15.4)

Hypersensitivity/infusion reaction

No. of patients with irAE	16 (3.0)	35 (3.4)
Time to onset (wk)	0.2 (0.2-1.8) ^{a)}	3.3 (2.2-4.1) ^{a)}
No. of patients with resolution	10 (100.0)	30 (85.7)
Time to resolution (wk)	0.1 (0.1-0.1)	0.1 (0.1-0.2)

Neurologic

No. of patients with irAE	-	-
Time to onset (wk)	NA	NA
No. of patients with resolution	-	-
Time to resolution (wk)	NA	NA

Values are presented as number (%) or median (95% CI). NIV, nivolumab; irAE, immune-related adverse event; NA, not available. ^{a)}p < 0.05 between the comparison of lung cancer and melanoma.